Indicative text 10th IMI Call published
IMI (Innovative Medicines Initiative) has published an indicative text of the 10th Call for proposals, which is scheduled for launch later this autumn. The 10th Call comprises one topic, on immunological assay standardisation and development for use in assessments of correlates of protection for influenza vaccines. The total available financial contribution from IMI will be maximum € 6,100,000. The indicative EFPIA 'in kind' contribution will be € 6,100,000. The duration of the project will be five years. All information regarding the Call is indicative and subject to change.
The 9th call October 9, 2013. An 11th Call for proposals will be probably launched at the end of this year.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.